ILD
Conditions
Brief summary
Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.
Interventions
BEHAVIORALAir Purifier (with Filter) Arm
Place an air purifier with high-efficiency filters in the home, and turn it on for at least 18 hours every day.
BEHAVIORALPurifier (without Filter) Arm
Place an air purifier without a filter in the home.
Sponsors
Peking Union Medical College
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with interstitial lung disease (ILD). * Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.
Exclusion criteria
* Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders. * A history of respiratory tract infection within the past two weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score) | Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase) | St. George's Respiratory Questionnaire (SGRQ):Score Range:Minimum score: 0 points;Maximum score: 100 points.A higher score indicates worse outcomes for the patient. |
| Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity) | Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase) | — |
| Quality of Life Indicators (e.g., CAT Score) | Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase) | COPD Assessment Test (CAT):It is a short, validated, patient-reported outcome (PRO) tool specifically designed to measure the impact of pulmonary disease on a patient's health status and daily life.Score Range:Minimum score: 0 points;Maximum score: 40 points.A higher score indicates worse health status and greater pulmonary disease-related burden for the patient. |
| Blood Sample Indicators (e.g., Concentration of Interleukin-8) | Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase) | Assessment of Changes in Pulmonary Inflammation or Lung Injury Before and After Intervention Using Concentrations of Biomarkers Such as Interleukin-8 |
Outcome results
None listed